Osimertinib for an older de novo T790M patient with chronic kidney disease

Osimertinib for an older de novo T790M patient with chronic kidney disease Dear Editor,Osimertinib yielded significantly greater efficacy than did platinum therapy plus pemetrexed in patients with T790M‐positive advanced non‐small cell lung cancer (NSCLC; including those with central nervous system metastases) in whom the disease had progressed during first‐line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKI) therapy. Just 5% of the patients discontinued osimertinib owing to an adverse effect. Among the reported deaths, the only death possibly related to treatment as reported by the investigator was as a result of interstitial lung disease. An improvement or stability of the lung cancer symptoms and functioning domains of quality of life was observed with osimertinib. Owing to the increase in the incidence of lung cancer among older individuals, the efficacy and safety of EGFR‐TKI for the treatment of older patients with NSCLC have recently garnered interest. Aging is associated with poor performance status. As osimertinib has finally been approved for clinical use, rebiopsies are often required in lung cancer patients who are positive for EGFR mutations and currently undergoing treatment.In this report, we present an advanced NSCLC patient who was unsuitable for chemotherapy because of chronic kidney disease (CKD) as a result of diabetes mellitus, and therefore was started on osimertinib at http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Geriatrics & Gerontology International Wiley

Osimertinib for an older de novo T790M patient with chronic kidney disease

Loading next page...
 
/lp/wiley/osimertinib-for-an-older-de-novo-t790m-patient-with-chronic-kidney-0UFHJQNIwS
Publisher
Wiley
Copyright
© 2018 Japan Geriatrics Society
ISSN
1444-1586
eISSN
1447-0594
D.O.I.
10.1111/ggi.13230
Publisher site
See Article on Publisher Site

Abstract

Dear Editor,Osimertinib yielded significantly greater efficacy than did platinum therapy plus pemetrexed in patients with T790M‐positive advanced non‐small cell lung cancer (NSCLC; including those with central nervous system metastases) in whom the disease had progressed during first‐line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKI) therapy. Just 5% of the patients discontinued osimertinib owing to an adverse effect. Among the reported deaths, the only death possibly related to treatment as reported by the investigator was as a result of interstitial lung disease. An improvement or stability of the lung cancer symptoms and functioning domains of quality of life was observed with osimertinib. Owing to the increase in the incidence of lung cancer among older individuals, the efficacy and safety of EGFR‐TKI for the treatment of older patients with NSCLC have recently garnered interest. Aging is associated with poor performance status. As osimertinib has finally been approved for clinical use, rebiopsies are often required in lung cancer patients who are positive for EGFR mutations and currently undergoing treatment.In this report, we present an advanced NSCLC patient who was unsuitable for chemotherapy because of chronic kidney disease (CKD) as a result of diabetes mellitus, and therefore was started on osimertinib at

Journal

Geriatrics & Gerontology InternationalWiley

Published: Jan 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off